Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study

barbara.lempert Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC   —  Encouraging results from the first proof-of-concept ...

Ophthotech eyes $85M IPO to fund Phase III for drug against blindness cause

Ryan McBride After assembling a whopping $ 175 million financing deal this spring, Ophthotech has filed paperwork with the SEC to secure up to $ 85 million more in an initial public ...

GW Opens IND for Phase III Sativex Trial

barbara.lempert GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for ...

Afrezza Meets Phase III Endpoint

barbara.lempert MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes VALENCIA, Calif.–(BUSINESS WIRE)–MannKind ...

Acasti Announces Positive Phase II Open Label Clinical Trial Results

barbara.lempert LAVAL, Quebec, Aug. 13, 2013 (GLOBE NEWSWIRE) — Acasti Pharma (“Acasti” or the “Corporation”) (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies ...

Lilly: Lung Cancer Drug Meets Phase III Endpoint

barbara.lempert Lilly Announces Phase III Necitumumab Study Meets Primary Endpoint of Overall Survival Study found improved overall survival in patients with stage IV squamous ...

Novartis: Afinitor Fails Phase III Liver Cancer Trial

barbara.lempert Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival •    Everolimus did not show survival benefit ...

Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

barbara.lempert STOCKHOLM – August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show ...

Exparel Phase III Trial Fails to Meet Primary Endpoint

mia.burns EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint Based upon Ongoing Femoral Nerve Block Trial, sNDA Submission Still Planned ...

ViroPharma Ends Phase II Cinryze Study

barbara.lempert ViroPharma Provides Update On Phase 2 Clinical Evaluation Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) EXTON, ...

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin

barbara.lempert Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108) All amounts are in U.S. dollars (unless ...

Analysis Indicates that Phase III Trial for Takeda May Miss Primary Endpoint

mia.burns Takeda Announces Unblinding of Phase 3 Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer That Progressed Post-Chemotherapy Based ...
Page 5 of 11« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS